Humana Inc (HUM)

Humana (New York: HUM) is one of the largest health insurance companies in the United States, operating primarily through health maintenance organizations (HMOs) and Medicare Advantage plans. The company insures millions of Americans and makes its money not by processing claims on behalf of others, but by accepting the financial risk of their care directly—charging a fixed premium per member and keeping the difference if medical costs run below what was collected. This risk-bearing model is the defining feature of managed care, and it creates both opportunity and vulnerability.

A company that wins by controlling costs

The insurance company that profits when its members stay healthy is the one that will outlast all others.

Humana operates in a fundamentally different way from a traditional health insurance intermediary. Rather than earn fees for administering a health plan that someone else bears the financial risk of, Humana accepts the risk itself: it collects premiums from its members and employers, then pays medical claims from that pool. If medical costs are lower than premiums collected, Humana pockets the difference as profit. If costs spike above premiums, Humana absorbs the loss. This risk-bearing arrangement means the company’s entire economic incentive is to keep its members healthy and to negotiate care costs downward—the opposite of a fee-for-service system where more services mean more revenue.

Humana’s largest and most attractive business is Medicare Advantage, which insures Americans age 65 and older. The U.S. government funds the program by paying Humana a fixed monthly capitation per member, and Humana delivers all-in care (hospital, physician, prescription, often dental and vision) for that amount. If Humana delivers care below the capitation, it profits. Medicare Advantage plans also allow members to pay for supplemental benefits—dental, vision, hearing, wellness programs—which Humana can layer on top and sell profitably. Humana has grown aggressively in Medicare Advantage over the past two decades and now earns a majority of its profit from that segment.

The remainder of Humana’s business comes from Medicaid (state-funded insurance for lower-income Americans) and commercial health plans sold to employers and individuals. These segments are less profitable than Medicare Advantage because they are more price-competitive and face stricter state-level regulation, but they add scale and diversify the membership base.

The economics of medical underwriting

Humana’s financial performance hinges entirely on the accuracy of its medical underwriting—the process of calculating how much care each member will need and setting premiums (or, in the case of Medicare Advantage, accepting the government’s capitation) at a level that covers that care plus a margin for administrative costs and profit.

When Humana’s underwriting is accurate, margins are strong. When it is wrong—when actual medical costs significantly exceed what was modeled—profitability evaporates. This is why the health insurance industry experiences volatile earnings even when the underlying business is stable: a cohort of members shifts toward older, sicker populations; prescription drug costs spike unexpectedly; a new treatment protocol becomes standard and everybody gets it; a pandemic disrupts normal care patterns and causes a rush of deferred care afterward. Any of these can blow through an underwriting assumption and destroy a quarter or a year’s worth of profit.

Humana has also invested heavily in medical management tools: primary-care relationships with members, health coaching, disease-management programs for chronic conditions, care-coordination for high-need members, and partnerships with providers that let the company steer members toward efficient, high-quality care. The economics of risk-bearing make these investments rational—every dollar Humana saves on unnecessary care goes straight to the bottom line. Over time, the company that best manages its member population and constrains unnecessary care wins.

The Medicare Advantage gamble

Medicare Advantage has been extraordinarily profitable for Humana and its peers, but it carries regulatory and policy risk. The federal government sets the capitation rates that plans receive annually, and if Congress decides to reduce those rates, Humana’s revenue and profits compress immediately. Conversely, if Congress increases or stabilizes rates, Humana’s growth accelerates—which is what happened for years, inflating the Medicare Advantage market and making it irresistibly attractive to incumbents and new entrants alike.

The industry has also faced criticism for avoiding sicker beneficiaries and for use of restrictive prior-authorization processes that slow member access to care. Regulators have begun tightening rules on which medical services plans can require authorization for, which potentially increases Humana’s costs. Changes to how the government calculates risk-adjustment payments to plans (which are meant to account for member health status) can also significantly affect profitability.

Humana’s exposure to these policy variables is one of the core risks of owning the stock. A company that is profitable because of a specific government policy is vulnerable to changes in that policy.

The Anthem precedent and competitive strength

Humana faces competition from UnitedHealth Group (UNH), Anthem, Cigna, and regional players. UnitedHealth is larger and more diversified, with a substantial pharmacy-benefits business (OptumRx) and health-care provider operations (Optum Health) that give it leverage Humana lacks. Anthem is a major commercial and Medicaid player. But Humana is the dominant player in Medicare Advantage—it has the scale, the brand recognition among beneficiaries, and the infrastructure built explicitly for that segment.

The company is also tempered by its history. Humana has experienced underwriting losses and severe stock declines before (most recently in 2022 after aggressive membership growth and underestimation of medical costs in 2021 and 2022), which has made management more cautious. The company now focuses on profitable growth rather than membership growth at any cost.

Researching Humana

The 10-K filing (SEC CIK 0000049071) breaks results by segment (Medicare Advantage, Medicaid, commercial) and includes detailed disclosures of the membership count, the average revenue per member, and the medical-loss ratio (the percentage of premiums spent on claims—the lower the ratio, the more profitable). Watch these metrics closely: if the medical-loss ratio is rising, margins are compressing; if it is stable or falling, the company’s underwriting is working.

The earnings calls are essential for understanding the company’s underwriting philosophy and any shifts in strategy. Pay attention to management commentary on prior-authorization changes, regulatory pressure, government capitation rate expectations, and the company’s assessment of member health trends. For investors, Humana is ultimately a bet on the company’s ability to manage its member population efficiently and navigate the policy environment around Medicare Advantage.